Methods of Treating and Preventing Renal Cancer using Dimethane Sulfonate Compounds


This invention describes a series of dimethane sulfonate compounds based on NSC 281612 and compositions comprising a pharmaceutically-acceptable carrier and a compound, or a salt, that are suitable for the treatment of renal cancer. The anti-tumor activity of NSC 281612 has been established in vivo against human renal tumor xenografts in mice. Suitable dosing and administration schedules for treatment of renal tumors have also been determined in this study.

Currently only a few small molecule inhibitors are effective in patients with renal cell carcinoma. Approximately 30,000 patients per year are diagnosed with this disease but many of them are untreatable because of intrinsic drug resistance, and efficient drug transport and detoxification mechanisms.



Potential Commercial Applications: Competitive Advantages:
For treatment or prevention of renal cancer.   Have properties expected of some alkylating agents but, unlike conventional alkylating agents, possess specific activity against renal cell carcinoma.


Inventors:
Susan Mertins (NCI)
Susan Bates (NCI)
David Covell (NCI)
Geoffrey Patton (NCI)
Melinda Hollingshead (NCI)
Bahu Rao Vishnuvajjala (NCI)


Intellectual Property:
PCT Application No. PCT/US2005/037152
U.S. Pat: 7,989,501 issued 2011-08-02
U.S. Pat: 8,273,797 issued 2012-09-25


Licensing Contact:
Patrick McCue , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220

OTT Reference No: E-249-2005/0

Updated: 11/01/2012